

FOI 2993

2nd April 2025

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Question 1. Do you treat patients for Urothelial cancer (Yes or No)?

If No, where do you refer patients for treatment

Response:

Yes

Question 2. How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:

Atezolizumab (Tecentriq)

Avelumab (Bavencio)

Carboplatin single agent or in any other combination

Carboplatin with Gemcitabine

Carboplatin with Gemcitabine + Avelumab (Bavencio)

Carboplatin with Paclitaxel

Cisplatin single agent or in any other combination

Cisplatin with Gemcitabine

Cisplatin with Gemcitabine + Nivolumab (Opdivo)

Cisplatin with Gemcitabine + Avelumab (Bavencio)

Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda)

Nivolumab (Opdivo)

Pembrolizumab (Keytruda)

Other active systemic anti-cancer therapy

Palliative care only

Erdafitinib

Response:

This information is not recorded centrally and therefore retrieving it would involve a manual search of individual patient records. As such we cannot provide this information as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

In addition, it would not be appropriate to search through individual patient records for the purposes for responding to a FOI request, there would be no patient expectation that medical records would be used in this way.

Question 3. How many patients have been treated for metastatic Urothelial cancer in the past 3 months with the following systemic anti-cancer therapies:

Carboplatin single agent or in any other combination

Carboplatin with Gemcitabine

Carboplatin with Gemcitabine + Avelumab (Bavencio)

Carboplatin with Paclitaxel

Cisplatin single agent or in any other combination

Cisplatin with Gemcitabine

Cisplatin with Gemcitabine + Avelumab (Bavencio)

Response:

This information is not recorded centrally and therefore retrieving it would involve a manual search of individual patient records. As such we cannot provide this information as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

In addition, it would not be appropriate to search through individual patient records for the purposes for responding to a FOI request, there would be no patient expectation that medical records would be used in this way.

Question 4. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer?

If so, can you please provide the name of each trial along with the number of patients taking part?

Response:

There are currently no clinical trials for urothelial cancer open to recruitment in Northern Ireland.

Information on open trails can be viewed at <https://cancertrials.hscni.net>

Email: Foi.Team@Southerntrust.hscni.net